Medivation's business is built on the identification and rapid development of product candidates that have the potential to improve the standard of care in human diseases.

Drug/Indication Pre-Clinical Phase 1 Phase 2 Phase 3
MDV3100
AFFIRM
study in men previously treated with docetaxel-based chemotherapy
PREVAIL
study currently enrolling men with advanced prostate cancer who have not yet received chemotherapy
TERRAIN
study to compare MDV3100 with bicalutamide in men who have progressed on LHRH analogue therapy
Hormone-Naïve
study evaluating MDV3100 monotherapy in men who have not had any previous hormonal therapies

 

 

Print E-mail